|
|
Article: Cambrex Corporation Completes Chiral Intermediates Purchase
- Article from:
- PR Newswire
- Article date:
- January 9, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST RUTHERFORD, N.J., Jan. 9 /PRNewswire/ -- Cambrex Corporation (Amex: CBM), announced today the completion of its previously announced acquisition of Celgene Corporation's (Nasdaq: CELG) chiral intermediate business for $7.5 million plus a royalty on future sales of up to $7.5 million. Included in the transaction are the exclusive rights to Celgene's enzymatic technology for the production of chirally pure products for the pharmaceutical industry, including the current pipeline of third party products under development and the equipment and personnel associated with the business. Celgene retains the right to use the technology in its chiral agrochemical and chiral ...